Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody

Catalog # Availability Size / Price Qty
Detection of CXCL1/GRO alpha /KC/CINC‑1 in Human PBMCs Treated with LPS and Monensin by Flow Cytometry.
2 Images
Product Details
Citations (17)
Supplemental Products
Reviews (1)

Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody Summary

Species Reactivity
Human, Primate
Detects human CXCL1/GRO alpha /KC/CINC-1 in ELISAs and Western blots. In Western blots, this antibody shows approximately 20% cross-reactivity with recombinant human (rh) CXCL2/GRO beta and rhCXCL3/GRO gamma and no cross-reactivity with recombinant rat (rr)CINC-1, rrCINC-2 alpha, rrCINC-2 beta, rrCINC-3, rhMIP-1 alpha, recombinant mouse (rm)MIP-1 alpha, rmMIP-1 beta, rmMIP-1 beta, rhMIP-1δ, rmMIP-1 gamma, rmMIP-2, rhMIP-3 alpha, rmMIP-3 alpha, rrMIP-3 alpha, rhMIP-3 beta, or rmMIP-3 beta.
Monoclonal Mouse IgG2B Clone # 20326
Protein A or G purified from hybridoma culture supernatant
E. coli-derived recombinant human CXCL1/GRO alpha /KC/CINC-1
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.


Recommended Concentration
Western Blot
1 µg/mL
Recombinant Human CXCL1/GRO alpha /KC/CINC‑1 (Catalog # 275-GR)
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Intracellular Staining by Flow Cytometry
0.25 µg/106 cells
See below

Human/Primate CXCL1/GRO alpha Sandwich Immunoassay

Recommended Concentration
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human/Primate CXCL1/GRO alpha /KC/CINC‑1 Biotinylated Antibody (Catalog # BAF275)

Standard: Recombinant Human CXCL1/GRO alpha Protein (Catalog # 275-GR)

Measured by its ability to neutralize CXCL1/GRO alpha /KC/CINC­1­induced chemotaxis in the BaF3 mouse pro­B cell line transfected with human CXCR2. The Neutralization Dose (ND50) is typically 0.600 - 9.00 µg/mL in the presence of 10 ng/mL Recombinant Human CXCL1/GRO alpha /KC/CINC­1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Intracellular Staining by Flow Cytometry Detection of CXCL1/GROa/KC/CINC-1 antibody in Human PBMCs Treated with LPS and Monensin antibody by Flow Cytometry. View Larger

Detection of CXCL1/GRO alpha /KC/CINC‑1 in Human PBMCs Treated with LPS and Monensin by Flow Cytometry. Human peripheral blood mononuclear cell (PBMCs) treated with 1 µg/mL LPS for 24 hours and 3 µM monensin for 2 hours was stained with Mouse Anti-Human/Primate CXCL1/GROa/ KC/CINC-1 Monoclonal Antibody (Catalog # MAB275, filled histogram) or isotype control antibody (Catalog # MAB004, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005).

Neutralization Chemotaxis Induced by CXCL1/GRO alpha  and Neutralization by Human CXCL1/GRO alpha  Antibody. View Larger

Chemotaxis Induced by CXCL1/GRO alpha and Neutralization by Human CXCL1/GRO alpha Antibody. Recombinant Human CXCL1/GROa/KC/CINC-1 (Catalog # 275-GR) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human/Primate CXCL1/GROa/KC/CINC-1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human CXCL1/GROa/KC/CINC-1 Monoclonal Antibody (Catalog # MAB275). The ND50 is typically 0.600 - 9.00 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Preparation and Storage

Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Size / Price
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL1/GRO alpha/KC/CINC-1

The gene for CXCL1/GRO alpha was initially discovered in hamster cells, using subtractive hybridization techniques, as a message that is over-expressed in tumorigenic cells and in normal cells during growth stimulation. The hamster cDNA was cloned and used as a probe for the subsequent cloning of the human GRO cDNA. Independently, a cDNA encoding a secreted protein with melanoma growth stimulating activity (MGSA) was also cloned from a human melanoma cell line and found to be identical to GRO. In addition to the initially cloned GRO gene, now designated CXCL1, two additional GRO genes, GRO beta or MIP-2 alpha and GRO gamma or MIP‑2 beta, which shared 90% and 86% amino acid sequence homology, respectively, with CXCL1, have been identified. All three human GROs are members of the alpha (C-X-C) subfamily of chemokines.

The three GRO cDNAs encode 107 amino acid precursor proteins from which the N-terminal 34 amino acid residues are cleaved to generate the mature GROs. There are no potential N-linked glycosylation sites in the amino acid sequences. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes, and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.

Similar to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. All three GROs can bind with high affinity to the IL-8 receptor type B. It remains to be seen if a unique GRO receptor(s) also exist. The rat homolog of human CXCL1, CINC, is much more active than human CXCL1 on rat neutrophils, suggesting that this cytokine may have selective species specificity.

Entrez Gene IDs
2919 (Human); 14825 (Mouse); 81503 (Rat)
Alternate Names
CINC1; CINC-1; CXCL1; FSP; GRO alpha; GRO1; GROa; KC; MGSA; MGSA-a; MGSA-alpha; NAP-3; SCYB1

Product Datasheets

You must select a language.


Citations for Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

17 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. RanBP1: A Potential Therapeutic Target for Cancer Stem Cells in Lung Cancer and Glioma
    Authors: YJ Kahm, IG Kim, RK Kim
    International Journal of Molecular Sciences, 2023-04-06;24(7):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  2. Orally-active, clinically-translatable senolytics restore alpha-Klotho in mice and humans
    Authors: Y Zhu, LGPL Prata, EOW Gerdes, JME Netto, T Pirtskhala, N Giorgadze, U Tripathi, CL Inman, KO Johnson, A Xue, AK Palmer, T Chen, K Schaefer, JN Justice, AM Nambiar, N Musi, SB Kritchevsk, J Chen, S Khosla, D Jurk, MJ Schafer, T Tchkonia, JL Kirkland
    EBioMedicine, 2022-03-13;0(0):103912.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  3. Eutopic endometrial immune profile of infertility-patients with and without endometriosis
    Authors: N Freitag, DM Baston-Bue, JS Kruessel, UR Markert, TN Fehm, AP Bielfeld
    Journal of reproductive immunology, 2022-01-29;150(0):103489.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  4. Neuronal impact of patient-specific aberrant NRXN1alpha splicing
    Authors: E Flaherty, S Zhu, N Barretto, E Cheng, PJM Deans, MB Fernando, N Schrode, N Francoeur, A Antoine, K Alganem, M Halpern, G Deikus, H Shah, M Fitzgerald, I Ladran, P Gochman, J Rapoport, NM Tsankova, R McCullumsm, GE Hoffman, R Sebra, G Fang, KJ Brennand
    Nat. Genet., 2019-11-29;51(12):1679-1690.
    Species: Human
    Sample Types: Cells
    Applications: Flow Cytometry
  5. Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
    Authors: L Fong, A Hotson, J Powderly, M Sznol, RS Heist, TK Choueiri, S George, BG Hughes, MD Hellmann, DR Shepard, BI Rini, S Kummar, AM Weise, MJ Riese, B Markman, LA Emens, D Mahadevan, JJ Luke, G Laport, JD Brody, L Hernandez-, P Bonomi, JW Goldman, L Berim, DJ Renouf, RA Goodwin, B Munneke, PY Ho, J Hsieh, I McCaffery, L Kwei, SB Willingham, RA Miller
    Cancer Discov, 2019-11-15;0(0):.
    Species: Human
    Sample Types: Cells
    Applications: Flow Cytometry
  6. Neutrophil Activities in Human Ocular Toxoplasmosis: An In Vitro Study With Human Cells
    Authors: LM Ashander, S Lie, Y Ma, E Rochet, JM Washington, JM Furtado, B Appukuttan, JR Smith
    Invest. Ophthalmol. Vis. Sci., 2019-11-01;60(14):4652-4660.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  7. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
    Authors: SE Logue, EP McGrath, P Cleary, S Greene, K Mnich, A Almanza, E Chevet, RM Dwyer, A Oommen, P Legembre, F Godey, EC Madden, B Leuzzi, J Obacz, Q Zeng, JB Patterson, R Jäger, AM Gorman, A Samali
    Nat Commun, 2018-08-15;9(1):3267.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  8. Tumor Microenvironment in Functional Adrenocortical Adenomas: Immune Cell Infiltration in Cortisol-producing Adrenocortical Adenoma
    Authors: Y Kitawaki, Y Nakamura, F Kubota-Nak, Y Yamazaki, Y Miki, S Hata, K Ise, K Kikuchi, R Morimoto, F Satoh, H Sasano
    Hum. Pathol., 2018-03-27;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  9. CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma
    Authors: EK Kim, S Moon, DK Kim, X Zhang, J Kim
    PLoS ONE, 2018-01-23;13(1):e0188847.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory FADDosome Complex upon TRAIL Stimulation
    Authors: CM Henry, SJ Martin
    Mol. Cell, 2017-02-16;65(4):715-729.e5.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  11. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
    Authors: Kelvin K Tsai
    J. Exp. Med., 2016-11-23;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  12. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke.
    Authors: Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, Orthey E, Arumugam T, Leypoldt F, Simova O, Thom V, Friese M, Prinz I, Holscher C, Glatzel M, Korn T, Gerloff C, Tolosa E, Magnus T
    Blood, 2012-09-13;120(18):3793-802.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  13. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue.
    Authors: Oladipo O, Conlon S, O'Grady A
    Br. J. Cancer, 2011-02-01;104(3):480-7.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  14. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1.
    Authors: Meen AJ, Oynebraten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, Kolset SO
    J. Biol. Chem., 2010-11-12;286(4):2636-47.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  15. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines.
    Authors: Moscova M, Marsh DJ, Baxter RC
    Cancer Res., 2006-02-01;66(3):1376-83.
    Species: Human
    Sample Types: Whole Cells
    Applications: Immunodepletion
  16. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
    Authors: Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H
    J. Immunol., 2005-11-01;175(9):6177-89.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Neutralization
  17. Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells.
    Authors: Hagiwara H, Mitsumata M, Yamane T
    Circulation, 1998-12-08;98(23):2584-90.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot


No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Primary Antibodies

Reconstitution Buffers

Secondary Antibodies

Reviews for Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody

Average Rating: 5 (Based on 1 Review)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Human/Primate CXCL1/GRO alpha /KC/CINC-1 Antibody
By Anonymous on 04/26/2017
Application: B/N Sample Tested: Neutrophils Species: Human

The migration speed of human neutrophils was test after treatment after treatment with anti-IL-8 (R&D) or anti-CXCL-1 (R&D).